Protein Lysine Methyltransferases Inhibitors.
Epigenetics
cancer
inhibitors
methylation
methyltransferases
protein lysine
small molecular
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
03
2022
revised:
31
05
2022
accepted:
20
06
2022
medline:
1
6
2023
pubmed:
1
9
2022
entrez:
31
8
2022
Statut:
ppublish
Résumé
Protein lysine methylation is a significant protein post-translational modification (PTMs) and has a key function in epigenetic regulation. Protein lysine methyltransferase (PKMTs) mainly catalyzes the lysine methylation of various core histones and a few non-histone proteins. It has been observed that aberrant activity of PKMTs has been found in many cancers and other diseases, and some PKMT inhibitors have been discovered and progressed to clinical trials. This field developed rapidly and has aroused great interest. In this paper, we reviewed the biochemical and biological activities of PKMTs and their association with various cancers. Selective small-molecule inhibitors, including their chemical structure, structure-activity relationship, and in vitro/vivo studies, are also described to provide ideas for the discovery of highly potent, selective PKMT inhibitors.
Identifiants
pubmed: 36043747
pii: CMC-EPUB-125988
doi: 10.2174/0929867329666220829151257
doi:
Substances chimiques
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
Lysine
K3Z4F929H6
Histones
0
Methyltransferases
EC 2.1.1.-
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3060-3089Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.